The month of November each year is dedicated to raising awareness of health issues affecting men, such as mental health and suicide prevention, prostate cancer and testicular cancer.

Prostate cancer is the fourth most common cancer worldwide and the second most common cancer in men after skin cancer, according to the World Cancer Research Fund International. Fortunately, prostate cancer is one of the most successfully treated types of cancer if caught early, which is why encouraging early screening measures is extremely important — especially as men with early prostate cancer are often asymptomatic, or present generic symptoms that can be caused by other health problems.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Prostate cancer is a major public health burden worldwide and especially within the UK. GlobalData’s epidemiologist forecast that incident cases of prostate cancer in the country are predicted to increase by 5.78% (60,133 cases) from 2024 to 2028. However, it appears that awareness raised by initiatives such as Men’s Health Awareness Month is encouraging men toward screening, as GlobalData’s epidemiologists also forecast that diagnosed prevalent cases are set to increase by
6.3% in the same period. The increased diagnosis will hopefully be supported by a wealth of novel predictive tools. One example is research recently published in JAMA Network Open, showing that two magnetic resonance imaging-based
risk calculators can predict prostate cancer risk among adults in Europe and North America with some accuracy. There is, however, still a long way to go towards the development of an effective predictive screening tool for prostate cancer.

A promising future for diagnosis and treatment

There is therefore a need for effective and innovative screening programmes as well as novel treatments, and attempts at both will likely materialise in the coming years as GlobalData forecasts that the prostate cancer market size is set to increase by

25% from $475.84 million in 2024 to $596.22 million by 2028. Hopefully, this is indicative of the innovation set to occur throughout this time.

GlobalData’s Trials Intelligence platform supports this, as data indicates that the number of prostate cancer clinical trials using an innovator drug has steadily increased since 2014 in parallel to the number of marketed prostate cancer therapies. Similarly, the number of drugs approved for prostate cancer is set to increase up to 2028.

Although there appears to be a slight dip in the number of innovator trials and therapies in 2024, the year is not yet complete and there is time to see these figures recover and possibly surpass previous years (Figure 1). Overall, the data predicts a promising future for the diagnostic and treatment landscape of prostate cancer. Initiatives such as Men’s Health Awareness Month are vital for early detection, which provides the greatest opportunity for potential sufferers to improve their chances of survival and quality of life.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Source: GlobalData, Pharma Intelligence Center (Accessed: November 2024)